Finerenone Also Slows Kidney Decline in Diabetes-Free Patients

Finerenone Also Slows Kidney Decline in Diabetes-Free Patients

(MedPage Today) -- Finerenone (Kerendia) slowed the decline of kidney function in adults with chronic kidney disease (CKD) who did not have diabetes, the large randomized FIND-CKD trial showed. By month 32, the mean annual rate of change in estimated...

Major trials show finerenone preserves kidney function beyond diabetes

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease (CKD) than it is currently recommended for.

Chronic Kidney Disease to become leading cause of premature death by 2040: Studies

FIND-CKD is a major international clinical trial that evaluated the effectiveness of finerenone in slowing kidney disease progression among people with chronic

Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease

WHIPPANY, N.J.--(BUSINESS WIRE)--Jun 5, 2026-

Finerenone Slows Kidney Function Decline in Non-Diabetic CKD: ERA 2026

Finerenone reduced kidney function decline and cardiovascular-kidney events in non-diabetic CKD. Find out more from the FIND-CKD trial.

Trial links KERENDIA to slower kidney decline in non-diabetic disease

Phase III FIND-CKD data show finerenone slowed eGFR loss and cut a composite kidney-cardiovascular risk versus placebo in 1,584 adults with non-diabetic CKD.